Clinical Research
Filter News
Found 120,932 articles
-
Despite promising Phase I data for its CRISPR-based allogeneic CAR-T therapy, CRISPR Therapeutics may have a safety issue to contend with.
-
As we resign ourselves to the fact that the epic SARS-CoV-2 virus that dominated 2020 is going to stubbornly follow us into 2021, we need to learn how to co-exist in temporary tolerance, at least until we have an effective vaccine.
-
Pfizer is continuing to invest in gene therapy research and development and other areas going on throughout the company, specifically in its North Carolina sites in Chapel Hill and Kit Creek.
-
With an initial capital of $50 million, MD Anderson and partner The Focus Fund hope to invest in small biotechs with big cancer-fighting potential.
-
NephCure Kidney International, Retrophin, AAKP Release Call to Action for Revolutionizing Rare Kidney Disease Diagnosis, Treatment, and Education
10/21/2020
NephCure Kidney International and Retrophin, in partnership with the American Association of Kidney Patients (AAKP), today released an expert paper with policy recommendations to coincide with American So
-
Aidoc granted AI industry-first FDA clearance for triage of incidental pulmonary embolism
10/21/2020
This is the company's 6th FDA clearance and further solidifies its leadership as the most comprehensive acute AI vendor in the market
-
Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud
10/21/2020
Series of Scientific Publications Demonstrate up to 99% Reduction of Airborne Respiratory Droplets Including Those not Captured by Surgical Masks Commercial Launch Provides Immediate, Broad Availability with Pulmatrix to Receive Escalating Royalties on Product Sales
-
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi® and Submits Market Authorization Application in Switzerland
10/21/2020
EffRx Pharmaceuticals Signs Exclusive License Agreement with Diurnal for the Registration and Commercialization of Alkindi ® and Submits Market Authorization Application in Switzerland FREIENBACH, Switzerland--( BUSINESS WIRE )-- EffRx Pharmaceuticals SA, a commercial-stage company that commercializes niche and orphan medicines in Switzerland and Europe, today announced it has recently entered into an exclusive license agreement with Diurnal Group plc, a
-
RegeneRx Closes Convertible Debt Financing
10/21/2020
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it has completed a $500,000 convertible debt financing. The funds will be used for operations while awaiting completion of its phas
-
Precision Genetics Advances COVID-19 Testing by Adding Saliva Collection Under Existing EUA
10/21/2020
Precision Genetics, a leading healthcare technology company and high capacity molecular testing lab, has added saliva collection to their existing portfolio of validated Covid-19 testing options submitted under Emergency Use Authorization (EUA) by the Food and Drug Administration. Precision Genetics sur
-
Mycovia Pharmaceuticals, Inc. Announces Last Patient Completes Final Visit in their Global Phase 3 “VIOLET Studies” for Oteseconazole (VT-1161) for the Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
10/21/2020
Mycovia Pharmaceuticals, Inc. (“Mycovia”) , an emerging biopharmaceutical company dedicated to recognizing and empowering those living with unmet medical needs by developing novel therapies, today announced that the last patient has completed their final visit in Mycovia’s Phase 3 pivotal clinical trials of oteseconazole (VT-1161) in patients with recurrent vulvovaginal
-
Neumentum and Nuance Biotech Enter into Licensing Agreement for NTM-001 (ketorolac for IV infusion) in China
10/21/2020
Neumentum Inc., a pharmaceutical company dedicated to transforming the way pain is treated – without opioids – today announced that the company has entered into a license agreement with Nuance Biotech Co. Ltd (Nuance), a China based specialty pharmaceutical company, providing Nuance with the exclusive rights to develop and commercialize Neumentum’s novel ketorolac for IV infusion (NTM-001) in China. NTM-001, is a novel, alcohol-free formulati
-
Immutep Granted European Patent for IMP761
10/21/2020
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of a new patent (number 3344654) entitled “Anti-LAG-3 Antibodies” by the European Patent Office. The claims of the patent are directed to Immutep’s pre-clinical product candidate, IMP761, and also to the use of IMP761 in the treatment o
-
SPARK, Pew's Platform for Antibiotic Discovery Research, Receives New Data from Merck and Kyorin
10/21/2020
The Pew Charitable Trusts announced today that Merck & Co. Inc. (known as MSD outside the U.S. and Canada ) and Kyorin Pharmaceutical Co. Ltd. ( Japan ) have shared antibiotic research data on Pew's open-access Shared Plat
-
Ben-Gurion University Researchers Develop Machine Learning Platform to Streamline Clinical Trials
10/21/2020
Researchers at Ben-Gurion University of the Negev (BGU) have developed a novel platform to streamline clinical trials, lower costs, and increase the efficiency and success rate of the drug or medical device development process.
-
Crown Aesthetics Continues To Lead By Example, Demonstrating "Safety First" With Transfer Of PRP Manufacturing Facility To The USA
10/21/2020
Crown Aesthetics , a division of Crown Laboratories, Inc. and pioneers in advanced aesthetics solutions, sheds light on their dedication to patients' safety following the decision to move all production of ProGen PRP TM , their FDA 510k cleared Platelet Rich Plasma system, to a manufacturing facility in the United States as of December
-
RetinalGeniX™ Technologies Selects OPTIONTRAX for Equity Management
10/21/2020
RetinalGeniX ™ Technologies, Inc. https://retinalgenix.com/ announced today that it has awarded a contract to Plan Management Corporation (PMC) for use of their OPTIONTRAX Equity Plan and Cap Table Software. RetinalGeniX ™ Technologies is a private California -based medical technology company focused on prevention of bli
-
Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA
10/21/2020
Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol ® Cyclo™ for treatment of Niemann-Pick Disease Type C
-
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
10/21/2020
Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has entered into a research collaboration and commercial license agreement with ArsenalBio for the use of Teneobio’s UniDabs®, single-domain, human heavy chain only antibodies in Chimeric Antigen Receptor (CAR) T-cell therapy.
-
Artelo Biosciences Files Patent on Use of Fatty Acid Binding Protein 5 Inhibitors for Treating Psychological DisordersReports positive preclinical data in animal models
10/21/2020
Artelo Biosciences, Inc. (NASDAQ: ARTL) , a clinical stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate endogenous signaling pathways, including the endocannabinoid system, today announced that it has filed a method of use patent with the U.S. Patent and Trademark Office covering the use of Fatty Acid Binding Protein 5 (FABP5) inhibitors for the treatment of psychological disorders s